bezafibrate has been researched along with Diabetes Mellitus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (17.39) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Bloomgarden, ZT; Drexler, A | 1 |
| Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K | 1 |
| Cai, B; Flory, JH; Hennessy, S; Sha, D; Small, DS; Ten Have, TR | 1 |
| Mori, Y | 1 |
| Aoki, Y | 1 |
| Ishibashi, S | 1 |
| Bamberg, K; Camejo, G; Dahllöf, B; Kjellstedt, A; Ljung, B; Oakes, ND; Ostling, J; Svensson, L | 1 |
| Fujita, H; Hirose, H; Kawai, T; Miyashita, K; Ogawa, T; Saruta, T; Seto, Y; Ukeda, K; Yajima, K; Yamada, T; Yamamoto, Y | 1 |
| Ito, S; Kanno, T; Kobori, K; Kondo, A; Kotani, K; Maekawa, M; Manabe, M; Morita, H; Nakamura, H; Saito, K | 1 |
| Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP | 1 |
| Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Haim, M; Matas, Z; Motro, M; Tanne, D; Tenenbaum, A | 1 |
| Arai, N; Ebihara, K; Hosoda, K; Inada, Y; Ishii, T; Maruyama, K; Masuzaki, H; Nakano, S; Nakao, K; Shibata, N; Tanaka, T; Yamazaki, Y; Yasue, S | 1 |
| Bar-Shalev, A; Bar-Shalom, R; Frenkel, A; Israel, O; Keidar, Z; Rispler, S; Strauss, HW; Weiler-Sagie, M | 1 |
| Rüth, E; Vollmar, J | 1 |
| Holler, HD; Janka, HU; Mehnert, H; Standl, A | 1 |
| Dorda, W; Kostner, GM; Mühlhauser, I; Prager, R; Schernthaner, G; Zechner, R | 1 |
| Barasch, E; Behar, S; Benderly, M; Caspi, A; Goldbourt, U; Graff, E; Pelled, B; Reicher-Reiss, H; Reisin, L; Roguin, N | 1 |
| Abdella, N; Akanji, AO; Mojiminiyi, OA | 1 |
| Tada, N | 1 |
| Betteridge, DJ | 1 |
| Kostner, GM; Schernthaner, G | 1 |
6 review(s) available for bezafibrate and Diabetes Mellitus
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
[Uncoupling protein-3 in skeletal muscle].
Topics: Animals; Bezafibrate; Carrier Proteins; Diabetes Mellitus; Energy Metabolism; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Lipid Metabolism; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Uncoupling Protein 3 | 2002 |
[Glucose intolerance in liver diseases].
Topics: Bezafibrate; Diabetes Mellitus; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin Resistance; Liver Diseases | 2002 |
[Guideline for management of lipid metabolism].
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Primary Prevention; Risk; Simvastatin | 2002 |
[Overviews of fibrate].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
Lipid-lowering trials in diabetes.
Topics: Arteriosclerosis; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male | 2001 |
4 trial(s) available for bezafibrate and Diabetes Mellitus
| Article | Year |
|---|---|
Influence of fibrate treatment on malondialdehyde-modified LDL concentration.
Topics: Adult; Aging; Apolipoproteins B; Arteriosclerosis; Bezafibrate; Diabetes Complications; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Sex Characteristics | 2004 |
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Glyburide; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Patient Compliance | 1982 |
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Diabetes Mellitus; Female; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Phosphatidylcholine-Sterol O-Acyltransferase | 1982 |
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study.
Topics: Age Factors; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Fibrinogen; Humans; Hypertension; Israel; Male; Middle Aged; Motor Activity; Multivariate Analysis; Myocardial Infarction; Risk Factors; Sex Factors; Smoking; Triglycerides | 1995 |
13 other study(ies) available for bezafibrate and Diabetes Mellitus
| Article | Year |
|---|---|
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Fibrate use in diabetes: new concepts.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents | 2011 |
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate | 2011 |
Simulation study of instrumental variable approaches with an application to a study of the antidiabetic effect of bezafibrate.
Topics: Bezafibrate; Computer Simulation; Confounding Factors, Epidemiologic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Logistic Models; Models, Structural; Odds Ratio; Pharmacoepidemiology | 2012 |
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
Topics: Alkanesulfonates; Animals; Bezafibrate; Carbohydrate Metabolism; Cinnamates; Diabetes Mellitus; Fatty Acids; Glucose; Humans; Insulin Resistance; Lipid Metabolism; Male; Mass Spectrometry; Mice; Mice, Obese; Molecular Structure; Obesity; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured | 2002 |
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
Topics: Animals; Bezafibrate; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Glucose; Glucose Transporter Type 2; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monosaccharide Transport Proteins; Pancreas; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors | 2003 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones | 2005 |
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Topics: Aged; Bezafibrate; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Bezafibrate; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Hyperglycemia; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Organ Size; Oxidoreductases; Peroxisome Proliferator-Activated Receptors; RNA, Messenger; RNA, Small Interfering; Triglycerides | 2007 |
PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake.
Topics: Adult; Aged; Aged, 80 and over; Aging; Benzodiazepines; Bezafibrate; Diabetes Mellitus; Drug Interactions; Female; Fluorodeoxyglucose F18; Heart; Heart Diseases; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardium; Positron-Emission Tomography; Radiopharmaceuticals; Thyroxine; Tomography, X-Ray Computed; Whole-Body Counting | 2007 |
[Improvement in diabetes control by treatment with bezafibrate].
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Insulin; Male; Sulfonylurea Compounds; Triglycerides | 1982 |
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged | 2000 |
Apolipoproteins in diabetes mellitus.
Topics: Adult; Apolipoproteins; Bezafibrate; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Lipoproteins; Male | 1985 |